NR-047662.2 and in-vitro detection reagent, preparation or kit, applications and detection method

An in vitro detection and kit technology, applied in biochemical equipment and methods, DNA/RNA fragments, recombinant DNA technology, etc., can solve the problems of difficult clinical diagnosis and treatment, high sensitivity and low specificity of myoglobin, etc. The effect of enriching the pathogenesis

Inactive Publication Date: 2016-11-09
THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are some commonly used markers of myocardial injury in clinical practice, such as troponin, myoglobin, creatine kinase isoenzyme, etc., these myocardial injury markers have their own limitations: troponin has a long half-

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NR-047662.2 and in-vitro detection reagent, preparation or kit, applications and detection method
  • NR-047662.2 and in-vitro detection reagent, preparation or kit, applications and detection method
  • NR-047662.2 and in-vitro detection reagent, preparation or kit, applications and detection method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: A long-chain non-coding RNA NR_047662.2, the nucleic acid sequence of which is shown in SEQ ID No:1. The transcription region of the long-chain non-coding RNA NR_047662.2 (lncRNA NR_047662.2) described in this example is located on chromosome 8, with a starting position of 12,394,587-12,523,120 and a full length of 128,534 bp. The long-chain non-coding RNA NR_047662.2 described in this example can provide new blood biomarkers and therapeutic targets for the early diagnosis and prognosis monitoring of acute myocardial infarction, further enriching the research on the pathogenesis of acute myocardial infarction.

Embodiment 2

[0023] Example 2: As an optimization of the above example, the long non-coding RNA NR_047662.2 is isolated from human blood.

Embodiment 3

[0024] Example 3: A reagent for detecting long-chain non-coding RNA NR_047662.2 in vitro, including a pair of specific primers for amplifying long-chain non-coding RNA NR_047662.2, the pair of specific primers includes upstream primers and downstream primers, upstream The sequence of the primer is shown in SEQ ID No: 2, and the sequence of the downstream primer is shown in SEQ ID No: 3. The expression level of the lncRNA NR_047662.2 described in the present invention can be obtained by combining the reagents for in vitro detection of long-chain non-coding RNA NR_047662.2 in this embodiment and the DNA template and PCR reaction solution in the prior art. The expression level of lncRNA NR_047662.2 can be used for screening of acute myocardial infarction. The specific primer pair described in this example is suitable for the detection of SYBR Green, Taqman probes, molecular beacons, double-hybrid probes, and composite probes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biological engineering myocardial infarction related genes, and relates to a lncRNA NR-047662.2 and an in-vitro detection reagent, preparation or kit, applications and a detection method; the long non-coding RNA NR-047662.2 has a nucleic acid sequence as shown in SEQ ID No:1. The long non-coding RNA NR-047662.2 can provide new blood biomarkers and therapeutic targets for early diagnosis and prognosis monitoring of acute myocardial infarction, and further enriches the research on a pathogenesis of acute myocardial infarction.

Description

technical field [0001] The present invention relates to the technical field of bioengineering myocardial infarction-related genes, and is a reagent, preparation or kit, application and detection method of NR_047662.2 and in vitro detection, that is, lncRNA NR_047662.2 and a reagent, preparation or kit, and application of in vitro detection ,Detection method. Background technique [0002] Acute myocardial infarction (AMI) is a common clinical critical disease, and its incidence rate is increasing year by year. There are at least 500,000 new patients with myocardial infarction in my country every year. Myocardial infarction has become an important disease that endangers human health. The World Health Organization predicts that by 2020, acute myocardial infarction will become the leading cause of death in the world. Myocardial ischemia is the main cause of myocardial injury and necrosis in acute myocardial infarction. At present, myocardial injury markers, as sensitive and obj...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/113C12Q1/68
CPCC12N15/113C12N2310/10C12Q1/6883C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 马依彤杨毅宁李晓梅翟慧刘芬陈邦党谢翔宋宁黄光楠
Owner THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products